DOCSLIB.ORG

2019 Scientific Program Committee All Relationships Are Considered Compensated

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2019 Scientific Program Committee All Relationships Are Considered Compensated 2019 Scientific Program Committee All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution Patents, Stock and Other Travel, Royalties, Other Expert Other Name Employment Leadership Ownership Honoraria Consulting or Advisory Role Speakers' Bureau Research Funding Accommodations, Intellectual Testimony Relationship Interests Expenses Property Monica M. Leap Syntalogic, Syntimmune Abbvie (Inst), Agenus (Inst), Astellas Pharma (Inst), AstraZeneca Bertagnolli Therapeutics (Inst), Baxalta (Inst), Bayer Health (Inst), Breast Cancer Research Foundation (Inst), Bristol-Myers Squibb (Inst), Celgene (Inst), Complion (Inst), Eisai (Inst), Exelixis (Inst), Genentech (Inst), GHI Pharma (Inst), Gilead Sciences (Inst), GlaxoSmithKline (Inst), Incyte (Inst), Janssen (Inst), Jazz Pharmaceuticals (Inst), Leidos (Inst), Lexicon (Inst), Lilly (Inst), Matrex (Inst), Mayo Clinic (Inst), Merck (Inst), MGH (Inst), Millenium Pharamceuticals (Inst), Novartis (Inst), Patient Centered Outcomes Research Institute (PCORI) (Inst), Pfizer (Inst), Pharmacyclics (Inst), Robert Wood Johnson Foundation (Inst), Sagerock Advisors (Inst), Sanofi (Inst), Taiho Pharmaceutical (Inst), Takeda (Inst), Tesaro (Inst), Teva (Inst) Suzanne George Abbott Laboratories, AstraZeneca, Bayer, Blueprint ARIAD (Inst), Bayer (Inst), Blueprint Medicines (Inst), Deciphera UptoDate Bayer Research to Abbvie (I), Allergan (I) Medicines, Deciphera, Lilly (Inst), Novartis (Inst), Pfizer (Inst) Practice Melissa L. Araxes Pharma (Inst), Astellas Abbvie (Inst), Acerta Pharma (Inst), Adaptimmune (Inst), Amgen Abbvie, Astellas Pharma, Johnson Pharma (I), AstraZeneca (Inst), (Inst), Array BioPharma (Inst), AstraZeneca (Inst), BeiGene (Inst), AstraZeneca, Boehringer BeiGene (Inst), Boehringer BerGenBio (Inst), Birdie (Inst), Boehringer Ingelheim (Inst), Bristol- Ingelheim, Bristol-Myers Ingelheim (Inst), Bristol-Myers Myers Squibb (Inst), Checkpoint Therapeutics (Inst), Clovis Oncology Squibb, Clovis Oncology, Squibb (Inst), Calithera Biosciences (Inst), Corvus Pharmaceuticals (Inst), CytomX Therapeutics (Inst), Daiichi Sankyo, EMD (Inst), Celgene (Inst), Daiichi Sankyo (Inst), Dynavax (Inst), EMD Serono (Inst), Foundation Serono, Exelixis, Genentech/Roche (Inst), Guardant Medicine (Inst), G1 Therapeutics (Inst), Genentech/Roche (Inst), Genentech, Incyte, Health (Inst), Incyte (Inst), Loxo Genmab (Inst), Genocea Biosciences (Inst), Gritstone Oncology Merck, Pfizer, Sysmex, (Inst), Merck (Inst), Mersana (Inst), (Inst), Guardant Health (Inst), Hengrui Pharmaceutical (Inst), Incyte Vapotherm Mirati Therapeutics (Inst), Otsuka (Inst), Janssen (Inst), Kadmon (Inst), Lilly (Inst), Loxo (Inst), Lycera (I), Pfizer (Inst), Ribon Therapeutics (Inst), Merck (Inst), Mersana (Inst), Mirati Therapeutics (Inst), Neovia (Inst), Sanofi (Inst) Oncology (Inst), Novartis (Inst), OncoMed (Inst), Pfizer (Inst), Regeneron (Inst), Sanofi (Inst), Stem CentRx (Inst), Syndax (Inst), Tarveda Therapeutics (Inst) Ann H. Partridge Biostatistics Karla V. Ballman ARIAD, Medtronic, Takeda Prostate cancer Janssen signature patent Oncology, Lilly (Inst), Immune enrichment signature for response to trastuzumab in HER2+ breast cancer (Inst) Suzanne E. AstraZeneca Patent pending for Dahlberg a statistical model assessing tumor growth (Inst) Susan Halabi Eisai, Ferring Pharmaceuticals Kelley M. Kidwell Mallinckrodt Rosemarie Mick Editas Medicine Infiniti Medical Mei-Yin Polley Yu Shyr Aduro Biotech, GlaxoSmithKline, Janssen Research & Development, Novartis, Pfizer, Roche/Genentech Breast Cancer - Metastatic Roisin M. Clovis Oncology (Inst), Genentech/Roche (Inst), Macrogenics (Inst), Syndax Connolly Merck (Inst), Merrimack (Inst), Novartis (Inst), Puma Biotechnology (Inst) Olwen M. Hahn Via Oncology Cardinal Health (I) Pfizer Cardinal Health (I) Erika P. Boehringer Ingelheim (Inst), Abbvie (Inst), Acerta Pharma (Inst), ArQule (Inst), AstraZeneca (Inst), Amgen, AstraZeneca, Hamilton Cascadian Therapeutics (Inst), BerGenBio (Inst), Boehringer Ingelheim (Inst), Cascadian Bayer, Bristol-Myers Daiichi Sankyo (Inst), Eisai (Inst), Therapeutics (Inst), Clovis Oncology (Inst), Curis (Inst), CytomX Squibb, Clovis Oncology, Flatiron Health, Genentech/Roche Therapeutics (Inst), Daiichi Sankyo (Inst), eFFECTOR Therapeutics Eisai, EMD Serono, (Inst), Lilly (Inst), Mersana (Inst), (Inst), Eisai (Inst), EMD Serono (Inst), Fujifilm (Inst), Foundation Medicine, Pfizer (Inst), Puma Biotechnology Genentech/Roche (Inst), H3 Biomedicine (Inst), Hutchison Genentech, (Inst) MediPharma (Inst), Immunomedics (Inst), InventisBio (Inst), Kadmon Genentech/Roche, (Inst), Leap Therapeutics (Inst), Lilly (Inst), Lycera (Inst), Macrogenics Genzyme, Guardant (Inst), Mallinckrodt (Inst), MedImmune (Inst), Medivation (Inst), Health, Helsinn Mersana (Inst), Merus (Inst), Millennium (Inst), Novartis (Inst), Therapeutics, HERON, Nucana (Inst), OncoMed (Inst), Oncothyreon (Inst), Pfizer (Inst), Lexicon, Lilly, Medivation, PharmaMar (Inst), Radius Health (Inst), Regeneron (Inst), Rgenix Merck, Novartis, Pfizer, (Inst), Stem CentRx (Inst), Syndax (Inst), Syros Pharmaceuticals Roche, Sysmex, Tesaro (Inst), Taiho Pharmaceutical (Inst), Takeda (Inst), TapImmune Inc. (Inst), Tesaro (Inst), TetraLogic Pharmaceuticals (Inst), Verastem (Inst), Zymeworks (Inst) Virginia G. Celgene, Eisai, Celgene, Eisai, Eisai Kaklamani Genentech, Genentech Genomic Health, Novartis, Pfizer Sara M. Tolaney AstraZeneca, Eisai, Genentech, Bristol-Myers Squibb, Eisai, Exelixis (Inst), Genentech/Roche (Inst), Lilly, Merck, NanoString Lilly (Inst), Merck (Inst), Novartis (Inst), Pfizer (Inst) Technologies, Nektar, Novartis, Pfizer, Puma Biotechnology Nicholas C. AstraZeneca, Bicycle Therapeutics, AstraZeneca (Inst), Bio-Rad (Inst), Clovis Oncology (Inst), Inivata Turner Novartis, Pfizer, Roche, Tesaro (Inst), Pfizer (Inst), Roche (Inst) Breast Cancer -Local/Regional/Adjuvant Lior Z. Braunstein Eun-Sil S. Hwang Jacqueline S. Jeruss Erica L. Mayer Context Therapeutics, Eisai, Lilly, Myriad Genetics (Inst), Pfizer (Inst) Novartis, Pfizer Priyanka Almac Diagnostics, AstraZeneca, Bristol-Myers Squibb (Inst), Celgene (Inst), Cosmo Biosciences (Inst), Almac Diagnostics, Sharma Myriad Genetics, Novartis, Pfizer, Novartis (Inst) AstraZeneca TapImmune Vered Stearns Iridium Therapeutics Abbvie, Biocept, MedImmune, Novartis, Pfizer, Puma Biotechnology Immunomedics Julia R. White Qfix Intraop Medical (Inst) Qfix Cancer Prevention, Genetics, and Epidemiology Veda N. Giri John R. Goffin Amgen, Boehringer Ingelheim, AstraZeneca Bristol-Myers Squibb Erin W. Hofstatter Noelle K. Abbvie, AstraZeneca, Bayer, LoConte Celgene Mark E. Robson AstraZeneca, AstraZeneca, McKesson, Merck Abbvie (Inst), AstraZeneca (Inst), InVitae (Inst), Medivation (Inst), AstraZeneca Pfizer Myriad Genetics (Inst), Pfizer (Inst), Tesaro (Inst) Central Nervous System Tumors E. Antonio DNAtrix Merck Advantagene, Alcyone Amgen Patents related to Chiocca Lifesciences, DNAtrix, Insigthec, oncolytic virus NanoTX, Oncorus, Sigilon, technology, gene StemGen, Tocagen, ZIOPHARM therapy, Oncology microRNA, exosome, antibodies Timothy F. Notable Labs Abbvie, Agios, Alexion Global Coalition Cloughesy Pharmaceuticals, Boehringer for Adaptive Ingelheim, Boston Biomedical, Research Bristol-Myers Squibb, Celgene, 501(c)(3) Cortice, Deciphera, Genocea Biosciences, GW Pharmaceuticals, Human Longevity, Inc, Insys Therapeutics, KIYATEC, Lilly, Merck, NewGen Therapeutics, Notable Labs, Novartis, Novocure, Novogen, Oxigene, Pfizer, Puma Biotechnology, Roche/Genentech, Sunovion, Tocagen, VBI Vaccines, VBL Therapeutics, Wellcome Trust Evanthia Abbvie (Inst), Genentech/Roche Genentech/Roche (Inst), Merck (Inst) Galanis (Inst), Oncorus Monica Malik Developmental Immunotherapy and Tumor Immunobiology Sanjay Goel Oncolytics (Inst) I have a patent with a co-inventor, John Mariadason, Ph.D, entitled "Method Of Determining The Sensitivity Of Cancer Cells To EGFR Inhibitors Including Cetuximab, Panitumumab And Erlotinib.", Patent No. 20090258364 James L. Gulley Astellas Medivation (Inst), Bavarian Nordic (Inst), Bristol-Myers Squibb (Inst), EMD Serono (Inst), Merck (Inst), NantBioScience (Inst), Pfizer (Inst) Aparna Kalyan Samumed Bristol-Myers Squibb (Inst) Ross L. Levine Qiagen Loxo Incyte Novartis Celgene, Roche Heather L. Amgen, Calithera Biosciences, Bristol-Myers Squibb (Inst), Lilly (Inst), MedImmune (Inst), Merck Amgen, Calithera Lilly, OBI Pharma McArthur Immunomedics, Lilly, Merck, OBI (Inst), ZIOPHARM Oncology (Inst) Biosciences, Pharma, Peregrine Immunomedics, Lilly, Pharmaceuticals, Pfizer, Roche, Merck, OBI Pharma, Spectrum Pharmaceuticals, Syndax Puma Biotechnology, Roche, Spectrum Pharmaceuticals Matthew I. BioClin Therapeutics Acerta Pharma (Inst), Astellas Pharma (Inst), AstraZeneca (Inst), Roche/Genentech Milowsky Bristol-Myers Squibb (Inst), Clovis Oncology (Inst), Incyte (Inst), Inovio Pharmaceuticals (Inst), Merck (Inst), Pfizer (Inst), Roche/Genentech (Inst), Seattle Genetics (Inst), X4 Pharmaceuticals (Inst) Kurt A. Schalper Takeda Celgene, Shattuck Labs Moderna Therapeutics, Navigate BioPharma, Onkaido Therapeutics, Pierre Fabre, Surface Oncology, Takeda, Tesaro, Vasculox Padmanee Apricity (I), BioAtla (I), Amgen (I), Apricity (I), BioAtla, Own patent Sharma Codiak Biosciences BioMx, Codiak Biosciences (I), licensed to Jounce, (I), Constellation Constellation Pharmaceuticals, Own patents Pharmaceuticals, Forty Seven (I), ImaginAb (I), licensed to BMS, Forty Seven
Load more

Recommended publications
  • Amgen and Incyte – the Biotechnology Acquisition
    Amgen and Incyte – the biotechnology acquisition Ana Carolina Coelho Student number: 152416013 Dissertation written under the supervision of António Luís Borges de Assunção Dissertation submitted in partial fulfilment of requirements for the MSc in Finance, at the Universidade Católica Portuguesa, May 2018 Abstract The main goal of this dissertation is to study the hypothesis of an acquisition in the biotechnology industry, between Amgen (acquirer) and Incyte (target). Amgen is a U.S.-based biotechnology company currently facing a decrease in sales, mainly due to an increase in the market share of generic drugs and the rise of biosimilar products. To offset the poor performance, it is looking for an acquisition in its industry, for which Incyte could be a suitable target. Incyte belongs to the U.S.-biotechnology industry, and although it has a shy presence in the market with only two released drugs, its revenues are expected to increase significantly in the near future. The combination of these companies would allow knowledge transfer about research and development process of new drugs, a stronger position in Europe, and a higher investment power to apply in R&D. The combined company would be able to decrease the number of employees due to duplication of jobs and decrease the cost of sales, as the power over suppliers increases. The potential synergies are valued at $28,522.8 million, of which $16,739.2 million are more likely to be realized. The combined firm, after the introduction of synergies, is expected to generate the same or even higher returns than the sum of the stand- alone businesses and higher growth rates, fulfilling Amgen’s need of growth.
    [Show full text]
  • Biotechnology Worldwide
    Biotechnology Worldwide There are several countries that are making special efforts to both develop and capitalise on Biotechnology. Chief amongst them is America, though cutting edge work is also going on in the UK, Ireland, Germany, Korea, Singapore, China and Japan. • America is the world leader in biotechnology, it has 1,379 biotechnology companies and employs 174,000 people. It spends £9 billion on research into biotechnology. • The European market for goods and services dependent on biotechnology is currently estimated at £30 billion and is forecast to exceed £100 billion by the year 2005 • The UK leads Europe in biotechnology and employs 19,000 people • The UK has 300 dedicated biotechnology companies and a further 250-300 involved in broader bioscience related activities • The industrial sectors which stand to benefit from biotechnology are pharmaceutical, agriculture, food and drink, chemicals and environmental technologies • Germany is the second strongest country in Europe, with 332 companies but fewer products in development than the UK. UK The UK biotechnology industry is regarded as second only to the huge effort taking place in the States. UK biotechnology companies generate over a billion pounds in revenue; half of this is pumped back into research and development. The industry has particular strengths, for example: • Britain was a key player in the world wide project of sequencing the 30,000 genes of the human genome. The announcement of the first working draft of the human genome marks a significant step forward in our understanding of the way in which we understand and develop treatments for incurable genetic conditions.
    [Show full text]
  • Inozyme Pharma Expands Medical Leadership Team
    Inozyme Pharma Expands Medical Leadership Team Strengthens Inozyme’s Ability to Advance Lead Candidate, INZ-701, into Clinical Trials Boston, Mass., Nov. 14, 2019 – Inozyme Pharma Inc., a biotechnology company developing novel medicines to treat rare and life-threatening mineralization disorders, today announced the addition of three industry veterans to its leadership team: • Pedro Huertas M.D., Ph.D., as Chief Medical Officer, • Gus Khursigara Ph.D., as Vice President of Medical Affairs and Clinical Operations, and • Catherine Nester, as Vice President of Physician and Patient Strategies. The executives will be instrumental in advancing Inozyme’s lead drug candidate, INZ-701, into clinical trials in 2020 for the treatment of patients with ENPP1 deficiency. INZ-701 is the first therapy that addresses the pathology of ENPP1 deficiency, including diseases such as generalized arterial calcification of infancy (GACI) type 1 and autosomal recessive hypophosphatemic rickets type 2 (ARHR2), both of which are rare and life-threatening manifestations of this enzyme deficiency. Inozyme Pharma received orphan drug designation for INZ-701 in the US and EU in 2018. “We are pleased and excited to welcome Pedro, Gus and Catherine to the Inozyme team,” said Axel Bolte, co-founder and chief executive officer of Inozyme. “Their expertise in orphan drug development – spanning medical affairs, regulatory affairs and clinical development – will strengthen and accelerate our ability to bring potentially life-saving medicines to people who urgently need effective treatments.” Dr. Huertas, a veteran of the pharmaceutical industry, has extensive experience in research and development and medical and regulatory affairs, especially regarding rare disorders and enzyme replacement therapies.
    [Show full text]
  • Citi Pure Earnings Growth US Long-Short Net TR Index (CIISGRUN)
    Date: 20-Aug-21 Index Weights as of monthly rebalance date 10-Aug-21 Citi Pure Earnings Growth US Long-Short Net TR Index (CIISGRUN) Long Exposure Short Exposure Constituent Bloomberg Ticker Constituent Name Weight(%) Constituent Bloomberg Ticker Constituent Name Weight(%) 1 AAP UN Equity Advance Auto Parts Inc 0.24% 1 A UN Equity Agilent Technologies Inc -0.12% 2 ABBV UN Equity AbbVie Inc. 0.59% 2 HWM UN Equity Alcoa Inc -1.02% 3 ABC UN Equity AmerisourceBergen Corp 0.06% 3 AAL UW Equity American Airlines Group Inc -1.09% 4 ADBE UW Equity Adobe Systems Inc 0.01% 4 AAPL UW Equity Apple Inc. -0.46% 5 ADM UN Equity Archer-Daniels-Midland Co 0.26% 5 ABMD UW Equity ABIOMED Inc -0.11% 6 ADSK UW Equity Autodesk Inc 0.26% 6 ABT UN Equity Abbott Laboratories -0.26% 7 AES UN Equity AES Corp 0.37% 7 CB UN Equity ACE Limited -0.07% 8 AIG UN Equity American Intl Group Inc 0.52% 8 ACN UN Equity Accenture plc -0.29% 9 AIZ UN Equity Assurant Inc 0.11% 9 ADI UW Equity Analog Devices Inc -0.13% 10 ALGN UW Equity Align Technology Inc 0.59% 10 ADP UW Equity Automatic Data Processing -0.76% 11 ALL UN Equity Allstate Corp 0.16% 11 AEE UN Equity Ameren Corp -0.24% 12 ALLE UN Equity Allegion PLC 0.34% 12 AEP UW Equity American Electric Power -0.23% 13 AMAT UW Equity Applied Materials Inc 0.59% 13 AFL UN Equity AFLAC Inc -0.29% 14 AMD UW Equity Advanced Micro Devices Inc 1.15% 14 AJG UN Equity ARTHUR J GALLAGHER & CO -0.23% 15 AME UN Equity AMETEK Inc 0.26% 15 AKAM UW Equity Akamai Technologies Inc -0.11% 16 AMT UN Equity American Tower Corp A 0.39% 16 ALB UN
    [Show full text]
  • Incyte Corporation 2016 Annual Report
    2016 ANNUAL REPORT TABLE OF CONTENTS Letter to Shareholders 2 Key Planned Goals for 2017 6 Innovation 7 Growth 10 Strength 13 Corporate Responsibility 15 Company Information 19 ii Incyte’s Executive Management Team LETTER TO SHAREHOLDERS Standing, left to right: Steven H. Stein, MD; Dear Shareholders, Paula J. Swain; Wenqing Yao, PhD; Jonathan E. Dickinson; At Incyte, we believe that innovation and the discovery of new products David W. Gryska; creates long-term value for patients and society, as well as for our employ- Hervé Hoppenot; Michael Morrissey; ees and our shareholders. It is our commitment to these objectives that has Vijay Iyengar, MD enabled us to make significant progress in the last year. During 2016, we saw continued growth in the number of patients being treated with Jakafi® Seated, left to right: Eric H. Siegel, JD, MBA; (ruxolitinib), our JAK1/JAK2 inhibitor, and we also added Iclusig® (ponati- Reid M. Huber, PhD; nib) to our commercial portfolio as part of our European transaction with Barry P. Flannelly, PharmD, MBA ARIAD Pharmaceuticals, Inc. In February 2017, with Eli Lilly & Company, we announced the European approval of Olumiant® (baricitinib). I believe that we are on Summary of Revenue-Generating Products track to reach our goal of PRODUCT NAME DRUG NAME TARGET APPROVED TERRITORY INDICATION(S) becoming a world-class, Jakafi® ruxolitinib1 JAK1/JAK2 Global MF3; PV4 Jakavi® global biopharmaceutical organization. For the first Iclusig® ponatinib BCR-ABL Europe CML and Ph+ ALL5 time in the history of our company, Incyte’s total Olumiant® baricitinib2 JAK1/JAK2 Europe RA6 yearly revenue surpassed $1 billion in 2016.
    [Show full text]
  • Massmutual Mid Cap Growth Fund T
    Fund Holdings As of 06/30/2021 MassMutual Mid Cap Growth Fund T. Rowe Price | Frontier Capital Prior to 5/1/2021, the Fund name was MassMutual Select Mid Cap Growth Fund. Fund Shares or Par Position Market Security Name Ticker CUSIP Weighting (%) Amount Value ($) Microchip Technology Inc MCHP 595017104 2.07 1,348,381 201,906,571 Agilent Technologies Inc A 00846U101 1.90 1,252,717 185,164,100 Hologic Inc HOLX 436440101 1.84 2,678,942 178,739,010 Teleflex Inc TFX 879369106 1.82 441,297 177,308,722 Ball Corp BLL 058498106 1.75 2,104,895 170,538,593 Textron Inc TXT 883203101 1.55 2,199,000 151,225,230 Burlington Stores Inc BURL 122017106 1.54 465,929 150,024,479 Catalent Inc CTLT 148806102 1.53 1,376,000 148,773,120 Marvell Technology Inc MRVL 573874104 1.46 2,442,368 142,463,325 Bruker Corp BRKR 116794108 1.39 1,776,000 134,940,480 Ingersoll Rand Inc IR 45687V106 1.29 2,564,000 125,148,840 The Cooper Companies Inc COO 216648402 1.28 314,645 124,684,374 KKR & Co Inc Ordinary Shares KKR 48251W104 1.25 2,050,813 121,490,162 Caesars Entertainment Inc CZR 12769G100 1.13 1,057,315 109,696,431 Reserve Invt Fds 0 76105Y208 1.07 103,877,547 103,877,547 DocuSign Inc DOCU 256163106 1.05 366,000 102,322,620 Chipotle Mexican Grill Inc CMG 169656105 1.04 65,283 101,210,846 Dollar General Corp DG 256677105 1.02 460,009 99,541,348 Veeva Systems Inc Class A VEEV 922475108 1.00 314,189 97,697,070 Avantor Inc AVTR 05352A100 0.98 2,700,000 95,877,000 JB Hunt Transport Services Inc JBHT 445658107 0.98 585,000 95,325,750 KLA Corp KLAC 482480100 0.97 291,710 94,575,299
    [Show full text]
  • Etf-Sparpläne
    ETF-SPARPLÄNE ISIN NAME IE00B8KGV557 ISHARES EDGE MSCI EM MIN VOL USD (ACC) IE00B86MWN23 ISHARES EDGE MSCI EUROPE MIN VOLATILITY EUR (ACC) IE00B8FHGS14 ISHARES EDGE MSCI WORLD MIN VOLATILITY USD (ACC) IE00B6SPMN59 ISHARES EDGE S&P 500 MIN VOL USD (ACC) IE00B87G8S03 ISHARES GLOBAL AAA-AA GOV BOND USD (DIST) DE0005933931 ISHARES CORE DAX EUR (ACC) IE0032523478 ISHARES CORP BOND LARGE CAP EUR (DIST) IE00B14X4T88 ISHARES ASIA PACIFIC DIVIDEND USD (DIST) IE00B1W57M07 ISHARES BRIC 50 USD (DIST) DE000A0F5UG3 ISHARES DOW JONES EU SUSTAINABLE EUR (DIST) IE00B6R52143 ISHARES AGRIBUSINESS USD (ACC) IE00B0M62Y33 ISHARES AEX EUR (DIST) DE000A0D8Q23 ISHARES ATX EUR (DIST) IE00B1FZSC47 ISHARES USD TIPS USD (ACC) IE00B14X4S71 ISHARES USD TREASURY BOND 1-3Y USD (DIST) IE00B1FZS798 ISHARES USD TREASURY BOND 7-10Y USD (DIST) IE00B1FZSD53 ISHARES GBP INDEX-LINKED GILTS GBP (DIST) IE00B6QGFW01 ISHARES EMERGING ASIA LOCAL GOV BOND USD (DIST) IE00B5M4WH52 ISHARES JPM EM LOCAL GOV BOND USD (DIST) IE00B3DKXQ41 ISHARES EURO AGGREGATE BOND EUR (DIST) IE00B3F81R35 ISHARES CORE EURO CORP BOND EUR (DIST) IE00B4L60045 ISHARES EURO CORP BOND 1-5Y EUR (DIST) IE00B4L5ZG21 ISHARES EURO CORP BOND EX-FIN EUR (DIST) IE00B4L5ZY03 ISHARES EURO CORP BOND EX-FIN 1-5Y EUR (DIST) IE00B6X2VY59 ISHARES EURO CORP BOND INT. RATE HEDGED (DIST) IE00B14X4Q57 ISHARES EURO GOV BOND 1-3Y EUR (DIST) IE00B4WXJH41 ISHARES EURO GOV BOND 10-15Y EUR (DIST) IE00B1FZS913 ISHARES EURO GOV BOND 15-30Y EUR (DIST) IE00B1FZS681 ISHARES EURO GOV BOND 3-5Y EUR (DIST) IE00B4WXJG34 ISHARES EURO GOV BOND
    [Show full text]
  • Guidelines with Regard to the Composition, Calculation and Management of the Index
    INDEX METHODOLOGY Solactive Pharma Breakthrough Value Index Version 2.1 dated September 03, 2020 Contents Important Information 1. Index specifications 1.1 Short Name and ISIN 1.2 Initial Value 1.3 Distribution 1.4 Prices and Calculation Frequency 1.5 Weighting 1.6 Index Committee 1.7 Publication 1.8 Historical Data 1.9 Licensing 2. Composition of the Index 2.1 Selection of the Index Components 2.2 Ordinary Adjustment 2.3 Extraordinary Adjustment 3. Calculation of the Index 3.1 Index Formula 3.2 Accuracy 3.3 Adjustments 3.4 Dividends and other Distributions 3.5 Corporate Actions 3.6 Correction Policy 3.7 Market Disruption 3.8 Consequences of an Extraordinary Event 4. Definitions 5. Appendix 5.1 Contact Details 5.2 Calculation of the Index – Change in Calculation Method 2 Important Information This document (“Index Methodology Document”) contains the underlying principles and regulations regarding the structure and the operating of the Solactive Pharma Breakthrough Value Index. Solactive AG shall make every effort to implement regulations. Solactive AG does not offer any explicit or tacit guarantee or assurance, neither pertaining to the results from the use of the Index nor the Index value at any certain point in time nor in any other respect. The Index is merely calculated and published by Solactive AG and it strives to the best of its ability to ensure the correctness of the calculation. There is no obligation for Solactive AG – irrespective of possible obligations to issuers – to advise third parties, including investors and/or financial intermediaries, of any errors in the Index.
    [Show full text]
  • List of Section 13F Securities, First Quarter, 2014
    List of Section 13F Securities First Quarter FY 2014 Copyright (c) 2014 American Bankers Association. CUSIP Numbers and descriptions are used with permission by Standard & Poors CUSIP Service Bureau, a division of The McGraw-Hill Companies, Inc. All rights reserved. No redistribution without permission from Standard & Poors CUSIP Service Bureau. Standard & Poors CUSIP Service Bureau does not guarantee the accuracy or completeness of the CUSIP Numbers and standard descriptions included herein and neither the American Bankers Association nor Standard & Poor's CUSIP Service Bureau shall be responsible for any errors, omissions or damages arising out of the use of such information. U.S. Securities and Exchange Commission OFFICIAL LIST OF SECTION 13(f) SECURITIES USER INFORMATION SHEET General This list of “Section 13(f) securities” as defined by Rule 13f-1(c) [17 CFR 240.13f-1(c)] is made available to the public pursuant to Section13 (f) (3) of the Securities Exchange Act of 1934 [15 USC 78m(f) (3)]. It is made available for use in the preparation of reports filed with the Securities and Exhange Commission pursuant to Rule 13f-1 [17 CFR 240.13f-1] under Section 13(f) of the Securities Exchange Act of 1934. An updated list is published on a quarterly basis. This list is current as of March 15, 2014, and may be relied on by institutional investment managers filing Form 13F reports for the calendar quarter ending March 31, 2014. Institutional investment managers should report holdings--number of shares and fair market value--as of the last day of the calendar quarter as required by [ Section 13(f)(1) and Rule 13f-1] thereunder.
    [Show full text]
  • Annual Report
    ANNUAL REPORT 2019 MARCH 2020 To Our Shareholders Alex Gorsky Chairman and Chief Executive Officer By just about every measure, Johnson & These are some of the many financial and Johnson’s 133rd year was extraordinary. strategic achievements that were made possible by the commitment of our more than • We delivered strong operational revenue and 132,000 Johnson & Johnson colleagues, who adjusted operational earnings growth* that passionately lead the way in improving the health exceeded the financial performance goals we and well-being of people around the world. set for the Company at the start of 2019. • We again made record investments in research and development (R&D)—more than $11 billion across our Pharmaceutical, Medical Devices Propelled by our people, products, and and Consumer businesses—as we maintained a purpose, we look forward to the future relentless pursuit of innovation to develop vital with great confidence and optimism scientific breakthroughs. as we remain committed to leading • We proudly launched new transformational across the spectrum of healthcare. medicines for untreated and treatment-resistant diseases, while gaining approvals for new uses of many of our medicines already in the market. Through proactive leadership across our enterprise, we navigated a constant surge • We deployed approximately $7 billion, of unique and complex challenges, spanning primarily in transactions that fortify our dynamic global issues, shifting political commitment to digital surgery for a more climates, industry and competitive headwinds, personalized and elevated standard of and an ongoing litigious environment. healthcare, and that enhance our position in consumer skin health. As we have experienced for 133 years, we • And our teams around the world continued can be sure that 2020 will present a new set of working to address pressing public health opportunities and challenges.
    [Show full text]
  • Mount Allison University Endowment Fund Holdings As of December 31, 2017
    Mount Allison University Endowment Fund Holdings As of December 31, 2017 Security Name Market Value ($Can) EQUITY HOLDINGS Canadian Holdings 5N PLUS INC $ 155 ABSOLUTE SOFTWARE CORP $ 851 ACADIAN TIMBER CORP $ 302 ADVANTAGE OIL & GAS LTD $ 283,788 AECON GROUP INC $ 1,728 AFRICA OIL CORP $ 684 AG GROWTH INTERNATIONAL INC $ 1,163 AGELLAN COMMERCIAL REAL ESTATE $ 349 AGF MANAGEMENT LTD $ 990 AGNICO-EAGLE MINES LTD $ 427,207 AGT FOOD AND INGREDIENTS INC $ 653 AIMIA INC $ 832 AIR CANADA INC $ 325,411 AIRBOSS OF AMERICA CORP $ 315 ALACER GOLD CORP $ 1,289 ALAMOS GOLD INC $ 2,216 ALAMOS GOLD INC NEW COM CLASS A $ 4,877 ALARIS ROYALTY CORP $ 1,107 ALGOMA CENTRAL CORP $ 330 ALIMENTATION COUCHE-TARD INC $ 98,854 ALIO GOLD INC $ 472 ALLIED PROPERTIES REAL ESTATE INVESTMENT TRUST $ 2,575 ALTIUS MINERALS CORP $ 1,233 ALTUS GROUP LTD/CANADA $ 1,916 ANDREW PELLER LTD $ 1,448 ARGONAUT GOLD INC $ 656 ARTIS REAL ESTATE INVESTMENT TRUST $ 1,539 ASANKO GOLD INC $ 209 ATCO LTD $ 119,947 ATHABASCA OIL COP $ 703 ATS AUTOMATION TOOLING SYSTEMS INC $ 1,769 AURICO METALS INC $ 311 AUTOCANADA INC $ 1,128 AVIGILON CORP $ 1,258 B2GOLD CORP $ 29,898 BADGER DAYLIGHTING LTD $ 1,525 BANK OF MONTREAL $ 725,449 BANK OF NOVA SCOTIA $ 2,019,757 BARRICK GOLD CORP $ 459,749 BAYTEX ENERGY CORP $ 1,213 BCE INC $ 791,441 BELLATRIX EXPLORATION LTD $ 94 BIRCHCLIFF ENERGY LTD $ 1,479 BIRD CONSTRUCTION INC $ 731 1 Mount Allison University Endowment Fund Holdings As of December 31, 2017 Security Name Market Value ($Can) BLACK DIAMOND GROUP LTD $ 95 BLACKBERRY LIMITED $ 151,777 BLACKPEARL RESOURCES INC $ 672 BOARDWALK REAL ESTATE INVESTMENT TRUST $ 1,610 BONAVISTA ENERGY CORP $ 686 BONTERRA ENERGY CORP $ 806 BORALEX INC $ 2,276 BROOKFIELD ASSET MANAGEMENT INCORPORATED $ 672,870 BROOKFIELD INFRASTRUCTURE PARTNERS L.P.
    [Show full text]
  • Biopartnering Executive Summary
    BIOWORLD® BIOPARTNERING REPORT 2009: STRATEGIES AND PARADIGMS OF THE DEAL EXECUTIVE SUMMARY By Michael Harris, BioWorld Executive Editor and Amanda Lyle, BioWorld Managing Editor LIST OF CONTENTS Introduction and Analysis Trends Depressing First Half of 2008 in Worldwide Public Markets Drug/Device Combos Could Salvage Dropped Compounds A Match Made in Heaven; R&D Productivity Via Partnering Drug and Medical Device Deals: A Different Type of Partnership As Big Pharma Model Falters, Biotech Rides to the Rescue Deals to M&As: The Culture of False-Flagging, Shape-Shifting Notable Deals Autoimmune and Inflammation Deals Immunomedics Inks Potential $620M Deal with Nycomed ARYx Seeking New Partner for GI Program after P&G Bails Out UCB Licenses Keppra, Cimzia Rights in Japan Alizyme, Norgine Team Up in $67M Marketing Deal Bionomics Signs Merck Serono in MS, Autoimmune Partnership TransPharma Gets $35M in Osteo Deal with Lilly QLT Sells Acne Gel Product Aczone for $150M to Allergan Start-up TFT Adds NF-Kappa B Decoy Program from Anesiva Early Stage Antibody Nets EUSA $44M from GSK Scil, Pfizer Enter $250M Deal for Preclinical Osteo Drug Catalyst Partners with Centocor for Engineered Protease Drugs Galapagos Inks $395M Deal with Lilly for Osteo Drugs Alba Inks Ex-U.S./Japan Deal with Shire for Celiac Drug Excaliard Snags $15.5M and Isis Fibrosis Drugs Galapagos and Janssen in RA Partnership Axcan, Cellerix Deal for Adult Stem Cell Therapy Radius Grants Novartis Option to BA058 in Potential $500M Deal Microbia, Forest Collaborate: Up to $330M for
    [Show full text]